UDP-glucuronosyltransferases mediate coffee-associated reduction of liver fibrosis in bile duct ligated humanized transgenic mice.

BACKGROUND

Coffee consumption has been shown to reduce the risk of liver fibrosis and is capable of inducing human UDP-glucuronosyltransferase () genes. UGT1A enzymes act as indirect antioxidants catalyzing the elimination of reactive metabolites, which in turn are potent initiators of profibrotic mechanisms. The aim of this study was to analyze the role of genes as effectors of the protective properties of coffee in bile duct ligation (BDL) induced liver fibrosis.

METHODS

Fourteen days BDL with and without coffee pre- and co-treatment was performed in -WT and -SNP mice. Hepatic UGT1A mRNA expression levels, serum bilirubin and aminotransferase activities were determined. Liver fibrosis was assessed by collagen deposition, computational analysis of Sirius red tissue staining and expression of profibrotic marker genes. Oxidative stress was measured by hepatic peroxidase concentrations and immunofluorescence staining.

RESULTS

UGT1A transcription was differentially activated in the livers of -WT mice after BDL, in contrast to a reduced or absent induction in the presence of SNPs. Co-treated (coffee + BDL) -WT-mice showed significantly increased UGT1A expression and protein levels and a considerably higher induction compared to water drinking WT mice (BDL), whereas in co-treated -SNP mice absolute expression levels remained below those observed in -WT mice. Collagen deposition, oxidative stress and the expression of profibrotic markers inversely correlated with expression levels in -WT and SNP mice after BDL and coffee + BDL co-treatment.

CONCLUSIONS

Coffee exerts hepatoprotective and antioxidative effects activation of UGT1A enzymes. Attenuated hepatic fibrosis as a result of coffee-mediated UGT1A induction during cholestasis was detected, while the protective action of coffee was lower in a common low-function SNP haplotype present in 10% of the Caucasian population. This study suggests that coffee consumption might constitute a potential strategy to support the conventional treatment of cholestasis-related liver diseases.